Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.
Vivacity-MG3 Trial Confirms Nipocalimab’s Efficacy, Safety in Treating Generalized Myasthenia Gravis
January 23rd 2025Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.
Study Finds Many Randomized Clinical Trials Have Poorly Justified Exclusion Criteria
January 21st 2025Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include at least one poorly justified exclusion, most commonly affecting pregnant or lactating individuals.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
Talvey Plus Tecvayli Shows Promising Results in Multiple Myeloma but Raises Infection Concerns
January 9th 2025A Phase Ib/II dose escalation and expansion trial shows promising antitumor activity and durable responses with Talvey (talquetamab) plus Tecvayli (teclistamab) in the treatment of relapsed or refractory multiple myeloma, but a higher incidence of grade 3 or 4 infections.
Rybrevant Plus Lazcluze Shows Over One-Year Survival Boost in EGFR-Mutated NSCLC Patients
January 7th 2025Results from the Phase III MARIPOSA trial demonstrated the combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) significantly improves overall survival compared to the current standard of care, Tagrisso (osimertinib), for patients with EGFR-mutated advanced or metastatic non-small cell lung cancer.
Addressing Racial Disparities in Lupus Clinical Trials
January 6th 2025Study finds that addressing racial disparities in lupus clinical trials requires targeted education, increased diversity among trial staff, culturally sensitive recruitment strategies, and addressing social determinants of health to improve Black patient participation.
Carvykti Significantly Boosts Survival, MRD Negativity in Relapsed Multiple Myeloma
December 10th 2024Phase III CARTITUDE-4 trial shows Carvykti significantly improves minimal residual disease negativity rates, progression-free survival, and overall survival compared to standard therapies for patients with relapsed or refractory multiple myeloma, especially when used earlier in treatment.